文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

依洛尤单抗在急性心肌梗死PCI术前降LDL-C的随机临床试验

LDL Cholesterol Lowering With Evolocumab Before Percutaneous Coronary Intervention for Acute Myocardial Infarction: The AMUNDSEN Randomized Clinical Trial.
PubMed 文献 · JAMA · 2026-08-29

AMUNDSEN试验在2161例高危急性心梗PCI患者中比较依洛尤单抗(首剂术前注射)联合标准治疗与单用标准治疗。12个月时依洛尤单抗组82%达到LDL-C<55 mg/dL且较基线降幅≥50%,标准治疗组40%(调整OR 5.54,P<.001),但全因死亡或非计划心血管住院无显著差异。

要点

  • PCI术前启动依洛尤单抗可使82%患者1年达标,标准治疗仅40%。
  • 6周时依洛尤单抗组LDL-C中位数16 mg/dL,标准治疗组56 mg/dL。
  • 1年内全因死亡或非计划心血管住院无显著临床获益。

核心结论

  • 急性心梗PCI患者一线加用依洛尤单抗可快速持续降低LDL-C,1年超80%达标。
  • 随访1年未检测到临床获益,不支持PCSK9抑制剂具有超越标准治疗的急性多效性作用。

研究设计与样本

  • 国际、4期、前瞻性、随机、开放标签、盲法终点裁决研究,48个中心、6个国家。
  • 纳入高危STEMI(>55岁)或NSTEMI伴至少1项额外高危特征的成人,2021年9月29日至2025年5月22日入组。
  • 随机1:1接受依洛尤单抗140 mg皮下每2周1次共1年(首剂PCI术前)联合标准治疗(n=1087)或单用标准治疗(n=1074)。

主要发现

  • 共2161例随机患者,平均年龄67岁,男性1703例(79%),STEMI 1261例(58%),NSTEMI 900例(42%)。
  • 主要结局(12个月LDL-C<55 mg/dL且较基线降幅≥50%)依洛尤单抗组792/970(82%)vs 标准治疗组370/934(40%),调整OR 5.54(95%CI 4.50-6.82),P<.001。
  • 6周时LDL-C中位数依洛尤单抗组16 mg/dL vs 标准治疗组56 mg/dL。
  • 主要临床终点(12个月全因死亡或非计划心血管住院)依洛尤单抗组159/1087(14.6%)vs 标准治疗组165/1074(15.4%),调整OR 0.94(95%CI 0.73-1.19),P=.59。

关键数值与推荐

  • 主要结局达标定义:12个月LDL-C<55 mg/dL且较基线降低≥50%。
  • 主要临床终点:12个月全因死亡或非计划心血管住院。
  • 对照组标准治疗包括高强度口服降脂治疗,可按指南指征选择使用PCSK9抑制剂。

临床怎么用

  • 对高危急性心梗行PCI患者,可考虑在导管室术前启动依洛尤单抗以快速达标。
  • 依洛尤单抗联合高强度口服降脂可作为一线强化降脂策略。
  • 不应期待PCSK9抑制剂在1年内带来超越降脂的临床硬终点获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibition is recommended as second- or third-line lipid-lowering therapy after myocardial infarction (MI), resulting in prolonged periods of inadequate low-density lipoprotein cholesterol (LDL-C) control. Whether in-catheterization laboratory decision of PCSK9 inhibition, started before mechanical reperfusion, could improve LDL-C control and clinical outcomes at 1 year is unknown. OBJECTIVE: To evaluate evolocumab as first-line therapy vs standard care in patients with high-risk acute MI undergoing percutaneous coronary intervention (PCI). DESIGN, SETTING, AND PARTICIPANTS: This international, phase 4, prospective randomized, open, blinded end-point adjudication study was conducted at 48 sites in 6 countries. Adults with high-risk ST-elevation MI (STEMI; aged >55 years) or non-ST-elevation MI (NSTEMI) with 1 or more additional high-risk characteristics were enrolled beginning September 29, 2021, through May 22, 2025, with final follow-up on May 22, 2026. INTERVENTIONS: Patients were randomized 1:1 to receive evolocumab 140 mg subcutaneously every 2 weeks for 1 year (first injection before PCI) in addition to standard care (n = 1087) or standard care alone (n = 1074). Standard care included high-intensity oral lipid-lowering therapy with the optional PCSK9 inhibitor use per guideline indication in the control group. MAIN OUTCOMES AND MEASURES: The primary outcome was LDL-C less than 55 mg/dL and at least 50% reduction in LDL-C from baseline at 12 months. The main clinical end point was all-cause death or unplanned cardiovascular hospitalization at 12 months. RESULTS: Among 2161 randomized patients (mean age, 67 years; 1703 males [79%]; 1261 [58%] with STEMI; 900 [42%] with NSTEMI), the primary outcome was achieved in 792 of 970 patients (82%) with evolocumab vs 370 of 934 (40%) with standard care (adjusted odds ratio, 5.54 [95% CI, 4.50-6.82]; P < .001). At 6 weeks, median LDL-C was 16 mg/dL with evolocumab vs 56 mg/dL with standard care. The main clinical end point occurred in 159 of 1087 patients (14.6%) with evolocumab vs 165 of 1074 (15.4%) with standard care (adjusted odds ratio, 0.94 [95% CI, 0.73-1.19]; P = .59). CONCLUSIONS AND RELEVANCE: In patients with acute MI undergoing PCI, first-line evolocumab combined with high-intensity lipid-lowering therapy produced rapid and sustained LDL-C reduction, with more than 80% of patients reaching the guideline-recommended target at 1 year. However, no clinical benefit was detected during the first year of follow-up, arguing against clinically meaningful acute pleiotropic effects of PCSK9 inhibitors in addition to standard care. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04951856.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Montalescot G, Ferrari E, Souteyrand G, et al. LDL Cholesterol Lowering With Evolocumab Before Percutaneous Coronary Intervention for Acute Myocardial Infarction: The AMUNDSEN Randomized Clinical Trial. JAMA. 2026. PMID: 42666092. doi:10.1001/jama.2026.17302

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。